Development and characterization of novel fast-dissolving pentobarbital suppositories for pediatric procedural sedation and comparison with lipophilic formulations.

Biopharmaceutics Characterization Dissolution Excipients Formulation Pediatric Pentobarbital Sedation Suppositories

Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 30 06 2024
revised: 24 09 2024
accepted: 09 10 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

For pediatric radiological procedures (RP), pentobarbital sodium (PNa) can be used orally or rectally to replace intravenous anesthesia. Since no commercial PNa suppositories exist, they must be prepared by compounding pharmacies. This study aims to develop fast-dissolving PNa suppositories for fast pharmacological activity during RP. We prepared gelatin (G), gelatin/polyethylene glycol 4000 (GP), and polyethylene glycol 4000 (P) suppositories, with and without pH adjustment, and assessed their dosage uniformity (DU), softening time, rupture resistance, and in-vitro dissolution. An optimal formulation was selected, and PNa release was compared to that of fat-based suppositories using dissolution tests. Additionally, the quality control process (analytical performance, safety/eco-friendliness and productivity/practical effectiveness) of these formulas were compared using a RGB method. All hydrophilic formulas (HF) met the DU requirement (AV < 8 %) except for P (AV 15.62 ± 4 %). pH adjustment enhanced G and GP suppositories resistance to 2.2 ± 0.2 kg and 2.0 ± 0.3 kg, respectively, and allowed 100 % release of PNa in under 10 min. In contrast, lipophilic formulas released less than 80 % of PNa at best after 120 min. These results show the biopharmaceutical suitability of HF for RP compared to lipophilic ones, but a pharmacokinetic study is needed to confirm data.

Identifiants

pubmed: 39395653
pii: S0939-6411(24)00358-8
doi: 10.1016/j.ejpb.2024.114532
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114532

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Aurelien Freisz (A)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63003 Clermont-Ferrand, France.

Imen Dhifallah (I)

Université Clermont-Auvergne, UFR Pharmacie, UMR MEDIS, F-63001 Clermont-Ferrand, France.

Yoann Le Basle (YL)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Mireille Jouannet (M)

CHU Clermont-Ferrand, Pôle Pharmacie, F-63003 Clermont-Ferrand, France.

Philip Chennell (P)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Ghislain Garrait (G)

Université Clermont-Auvergne, UFR Pharmacie, UMR MEDIS, F-63001 Clermont-Ferrand, France.

Eric Beyssac (E)

Université Clermont-Auvergne, UFR Pharmacie, UMR MEDIS, F-63001 Clermont-Ferrand, France.

Yassine Bouattour (Y)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: ybouattour@chu-clermontferrand.fr.

Valérie Sautou (V)

Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France.

Classifications MeSH